Client News

Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound

InflaRx provides update on planned Phase III study design in pyoderma gangrenosum with vilobelimab and status of its EUA application in critically ill COVID-19 patients

Volta Medical secures €36M in Series B funding to support adoption of its AI software for cardiac ablation, new CFO introduced

Abivax publishes novel data with respect to obefazimod’s anti-inflammatory mechanism of action

LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles

Mainz Biomed provides year-end 2022 corporate review

Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Destiny Pharma announces year end Trading Update Good progress across all key projects in 2022

InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19

Abivax receives FDA agreement on pediatric development plan with obefazimod in IBD